ICER Views CAR-T Therapies Kymriah, Yescarta As Cost Effective
ICER's review of available clinical trial data along with associated treatment and hospital costs found that Novartis' Kymriah and Gilead/Kite's Yescarta generally would not break the health care bank.
You may also be interested in...
Proposed list of topics for review in 2019 by the Institute for Clinical and Economic Review includes a total of 15 drugs but that could change as the year goes on.
Leaders from Novartis and other companies developing cellular gene therapies share insights they've gleaned on manufacturing, clinical trials, and value-based pricing.
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.